Effient Beats Plavix In Cost Study, But Will Results Pass Muster With Payers?
Executive Summary
Lilly/Daiichi Sankyo's clot-buster Effient proved more cost-effective for acute coronary syndrome patients managed with percutaneous coronary intervention procedures than Bristol and Sanofi's soon-to-be generic Plavix in a large study funded by Lilly
You may also be interested in...
Lilly Rejects NICE Comparator For Efient In ACS, But Gains Approval Anyway
Despite Lilly's decision not to make an indirect comparison its chosen comparator, AstraZeneca’s Brilinta, NICE agrees that Lilly's Efient is cost-effective and sometimes clinically superior to standard care.
Germany's IQWiG Gives Partial Nod To AZ's Brilinta In First Added-Benefit Assessment
AstraZeneca's clot buster could benefit certain patients with Acute Coronary Syndromes, Germany's health technology assessors conclude.
Medco "Genetics For Generics" Research Anticipates Plavix Patent Loss
Medco is working to generate cost effectiveness data for Bristol-Myers Squibb's anti-clotting blockbuster Plavix in anticipation of the launch of clopidogrel generics in 2011